NL-OMON42878已完成不适用
An open label, single dose, single period study to assess the mass balance recovery, metabolite profile and metabolite identification of [14C] APD421 administered via the intravenous route to healthy male subjects - ADP421 Human ADME Study
Acacia Pharma0 个研究点目标入组 6 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •healthy male subjects
- •18-65 yrs, inclusive
- •BMI: 18.0-30.0 kg/m2, inclusive
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 3 months before the start of this study or being a blood donor within 3 months from the start of the study. In case of donating more than 100 ml of blood in the 3 months prior the start of this study.
研究者
相似试验
已完成
1 期
Mass balance study of [14C]-REN001 in healthy male subjectsPrimary mitochondrial myopathy (rare genetic diseases that cause muscles to not function properly)Genetic DiseasesISRCTN57533271Reneo Pharma Ltd6
进行中（未招募）
1 期
A Study evaluating the safety and efficacy of LNP023 in patients with a blood disorder called paroxysmal nocturnal hemoglobinuria (PNH)Paroxysmal Nocturnal Hemoglobinuria (PNH)MedDRA version: 20.0 Level: HLGT Classification code 10018911 Term: Haemolyses and related conditions System Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2017-000888-33-FRovartis Pharma AG10
进行中（未招募）
1 期
A Study evaluating the safety and efficacy of LNP023 in patients with a blood disorder called paroxysmal nocturnal hemoglobinuria (PNH)EUCTR2017-000888-33-DEovartis Pharma AG15
招募中
不适用
A randomized, open-label, and single-dose study to evaluate the safety and the pharmacokinetics after concurrent administration of UIC202007 and UIC202008 in healthy adult subjectsKCT0005901Korea United Pharm30
已完成
不适用
AN OPEN-LABEL, SINGLE-DOSE, SINGLE-PERIOD STUDY DESIGNED TO ASSESS THE MASS BALANCE RECOVERY, METABOLITE PROFILE AND METABOLITE IDENTIFICATION OF [14C]-OLOROFIM ADMINISTERED VIA THE ORAL ROUTE TO HEALTHY MALE SUBJECTS.Serious fungal infections10017528NL-OMON48360F2G Biotech GmBH12